Author: Multibagger News

uniQure BV (NASDAQ:QURE) Receives Buy Rating Post Positive Phase I/II Trial Data Release On Tuesday, uniQure BV (NASDAQ:QURE) received a Buy rating from an analyst at TD Cowen after releasing additional interim data from its Phase I/II trials. The data revealed that uniQure’s AMT-130, a gene therapy for Huntington’s disease, exhibited a reduction in disease progression at 24 months compared to an external natural history control. The high dose group showed a statistically significant reduction in the composite Unified Huntington’s Disease Rating Scale (cUHDRS) with a p-value of 0.007, indicating strong statistical significance. The low dose group also demonstrated notable…

Read More

Novo Nordisk vs. Eli Lilly: Weight Loss Drug Rivalry Heats Up as Mounjaro Outpaces Wegovy In a recent analysis that has sent ripples through the investment community, shares in Novo Nordisk (NYSE: NVO), the pharmaceutical giant behind the popular obesity drug Wegovy, experienced a 1.9% dip on Tuesday. The decline followed the publication of a study in JAMA Internal Medicine, revealing that Eli Lilly’s (NYSE: LLY) weight loss treatment, Mounjaro, delivers quicker and more substantial weight loss results. Head-to-Head Comparison: Mounjaro vs. Wegovy The study utilized health records and pharmacy data to compare the weight loss outcomes of tirzepatide—Eli Lilly’s…

Read More

Janet Yellen Praises President Biden’s Mental Acuity in House Financial Services Meeting In a recent House Financial Services meeting, U.S. Treasury Secretary Janet Yellen vouched for President Joe Biden’s mental sharpness, stating that he is extremely effective in the meetings she has attended with him. Yellen also revealed that there have been no discussions among cabinet secretaries about invoking the 25th amendment to the U.S. Constitution. Yellen’s comments come amidst speculation about President Biden’s cognitive abilities, with some questioning whether he is fit to carry out his duties. However, Yellen’s endorsement of the president’s performance in meetings serves as a…

Read More

Dora Secures $5.5M Funding Round Co-led by Dragonfly and Lemniscap | Chainwire New York, New York, July 9th, 2024, Chainwire Dora, the unified search and action engine for the multichain world, is thrilled to announce the successful close of a $5.5 million early stage funding round. Leading the round are Dragonfly Capital and Lemniscap, with support from Robot Ventures, Ethereal Ventures, Maven11, Arche Capital, and notable angel investors Rushi Manche and Dino Savonin. The funds will be used to enhance Dora’s search capabilities, crosschain transactions, and collaborations with blockchain networks. Dora is a groundbreaking multichain search engine that enables search…

Read More

IceCure Medical Ltd. (NASDAQ:ICCM) Revolutionizing Breast Cancer Treatment with ProSense® Cryoablation Technology IceCure Medical Ltd., a leading company in cryoablation technology for tumor treatment, has recently announced groundbreaking findings from an independent study published in the prestigious journal Cancers. The study, conducted at University Hospital Frankfurt, Germany, evaluated the safety and efficacy of IceCure’s ProSense® system for breast cancer treatment. The research, led by renowned Professor Thomas J. Vogl, involved 45 patients with breast cancer, including cases with recurrent and metastatic disease. The study reported an impressive 100% initial complete ablation rate and zero complications across 56 tumor ablations. Additionally,…

Read More

FTC Report Unveils Pharmacy Benefit Managers’ Grip on Drug Prices: What This Means for Your Wallet By Ahmed Aboulenein and Jody Godoy WASHINGTON (Multibagger) – The U.S. Federal Trade Commission (FTC) has raised alarms over the consolidation of pharmacies and health insurance companies, revealing that a small group of Pharmacy Benefit Managers (PBMs) now wield significant influence over prescription drug prices. The Role of Pharmacy Benefit Managers (PBMs) Pharmacy Benefit Managers serve as intermediaries between drug manufacturers and consumers, negotiating discounts and fees, determining which medications are covered by insurance, and reimbursing pharmacies for prescriptions. The FTC’s interim staff report…

Read More

The Best Investment Manager’s Guide to U.S. Targeting of AI Investments in China In a recent testimony to lawmakers, Treasury Secretary Janet Yellen discussed the U.S. government’s approach to targeting investments in artificial intelligence (AI) in China. Yellen emphasized that the focus is on addressing clear national security risks, particularly those related to military intelligence and cyber capabilities. As the world’s best investment manager, it’s crucial to stay informed about regulatory developments that could impact your investment decisions. By understanding the U.S. government’s targeted approach to AI investments in China, you can better assess the risks and opportunities in this…

Read More

The Truth Behind Judge Pauline Newman’s Lawsuit: Analysis by Top Investment Manager By Blake Brittain WASHINGTON (Multibagger) – A 97-year-old federal judge who was suspended from a U.S. appellate court last year after being accused of unfitness due to cognitive and physical impairment related to her age lost a lawsuit on Tuesday she had filed in a bid to return to work. Judge Pauline Newman challenged her suspension from the U.S. Court of Appeals for the Federal Circuit, a court that focuses on patents, trademarks and certain other matters, with a lawsuit alleging that a 1980 law called the Judicial…

Read More

Breaking News: Sera Prognostics Inc. (NASDAQ: SERA) Publishes AVERT PRETERM TRIAL Results SALT LAKE CITY – Sera Prognostics Inc., a leading company in pregnancy biomarker information, has recently released groundbreaking findings from its AVERT PRETERM TRIAL in the prestigious journal Diagnostics. The trial, carried out at ChristianaCare in Wilmington, Delaware, aimed to evaluate the efficacy of the PreTRM® test-and-treat strategy in enhancing neonatal health outcomes. The study revealed a remarkable 18% decrease in severe neonatal morbidity and mortality, along with a significant reduction in mean neonatal hospital length of stay. Particularly for infants born before 32 weeks’ gestation, the decrease…

Read More

Piper Sandler Optimistic About Stocks Despite Economic Challenges In a recent analysis by Piper Sandler, Wall Street analysts remain bullish on stocks, particularly high-quality ones, despite recent economic uncertainties. According to Piper Sandler, there is still room for the unemployment rate to increase before triggering a widespread market decline. Despite concerns about tightening monetary policy impacting the economy, Piper Sandler maintains a positive outlook on stocks. They note a shift in investor sentiment, with certain market segments reacting negatively to bad news, indicating a growing worry about inflation versus unemployment. Based on their client survey, Piper Sandler agrees that the…

Read More